SGRL vs SYMBIOTEC: Stock Comparison
Metric snapshot
SGRL leads 0; SYMBIOTEC leads 0 of 4
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Price
| Metric | SGRL | SYMBIOTEC |
|---|---|---|
| Live Price | ₹655.6 | ₹1,038.6 |
| Day Change | 1.07% | -0.4% |
| Volume | 3,584 | 2.75 L |
| 52-Week High | ₹722 | ₹1,193.7 |
| 52-Week Low | ₹477.05 | ₹934.2 |
| Distance from 52W High | -9.2% | -12.99% |
Valuation
| Metric | SGRL | SYMBIOTEC |
|---|---|---|
| Market Cap | ₹0 Cr | ₹6,624 Cr |
| EPS | ₹0.87 | — |
| Book Value | ₹126.95 | — |
| Dividend Yield | 0% | 0% |
Growth
| Metric | SGRL | SYMBIOTEC |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 0% | — |
| Qtr Profit Growth | 0% | — |
Profitability & Leverage
| Metric | SGRL | SYMBIOTEC |
|---|---|---|
| Net Margin | 0% | 0% |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | SGRL | SYMBIOTEC |
|---|---|---|
| Promoter Holding | 72.84% | 33.28% |
| FII Holding | 0% | 21.08% |
| DII Holding | 0.52%▲ 0.52 pp | 27.52% |
| Public Holding | 26.64%▼ 0.52 pp | 18.12% |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: SHREE GANESH REMEDIES and SYMBIOTEC PHARMALAB.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.